Cancer screening company Nucleix raises $5m////////////////////////
< Back to all news
Orbimed Israel and Zohar Zisapel participated in the financing round.
Nucleix, which is developing a test for early detection of bladder cancer, has raised more than $5 million in an investment round led by venture capital firm OrbiMed Advisors LLC. One of the company?s private investors, Zohar Zisapel, participated in the current round as well. The company had raised $3 million before this round, primarily from private investors. Read More>>